| scholarly article | Q13442814 |
| P50 | author | Hans J van der Vliet | Q57051708 |
| Tanja D de Gruijl | Q90913412 | ||
| P2093 | author name string | Paul M P van Bergen en Henegouwen | |
| Henk M W Verheul | |||
| Famke L Schneiders | |||
| Renée C G de Bruin | |||
| Roeland Lameris | |||
| P433 | issue | 3 | |
| P921 | main subject | antibody | Q79460 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 153-165 | |
| P577 | publication date | 2014-08-20 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Critical Reviews in Oncology Hematology | Q15724423 |
| P1476 | title | Bispecific antibody platforms for cancer immunotherapy | |
| P478 | volume | 92 |
| Q47607160 | A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice |
| Q64974740 | A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®. |
| Q52731753 | A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. |
| Q58869554 | ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds |
| Q42655550 | Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors |
| Q38470166 | Arming oncolytic viruses to leverage antitumor immunity |
| Q55316979 | Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation. |
| Q41302727 | BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells |
| Q39746653 | Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications |
| Q34500896 | Cancer immunotherapy in veterinary medicine: Current options and new developments |
| Q38636711 | Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies |
| Q38837680 | Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma |
| Q33648086 | Clinical Pharmacology and Translational Aspects of Bispecific Antibodies |
| Q38364459 | Clinical pharmacology of bispecific antibody constructs. |
| Q38849985 | Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer |
| Q90312396 | Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer |
| Q51784482 | Development of a bispecific antibody tetramerized through hetero-associating peptides |
| Q42423743 | Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody |
| Q40745622 | Emerging concepts of T cell metabolism as a target of immunotherapy. |
| Q64098003 | Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology |
| Q47112037 | Enhancing the antitumor potency of T cells redirected by bispecific antibodies |
| Q36054765 | Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features |
| Q39279256 | Human Tumor Antigens Yesterday, Today, and Tomorrow |
| Q64227267 | Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy |
| Q38787696 | Immunotherapy for breast cancer: past, present, and future |
| Q89529544 | Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy |
| Q46492814 | Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach |
| Q38542034 | Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. |
| Q64883255 | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. |
| Q38728528 | Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody. |
| Q38970823 | Recombinant Antibody Fragments for Neurodegenerative Diseases |
| Q55021294 | Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy. |
| Q38324388 | Targeting T cell metabolism for therapy |
| Q26799372 | The Evolution of T-cell Therapies for Solid Malignancies |
| Q42323236 | The making of bispecific antibodies |
Search more.